DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
 - EconoTimes)
NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 23, 2017 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE:TEVA), if they purchased the Company’s American Depository Shares (“ADSs”) and/or shares on the Tel Aviv Stock Exchange between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
Get Help
Teva Pharmaceutical investors should visit us at https://www.claimsfiler.com/cases/view-teva-pharmaceutical-industries-ltd-american-depository-shares-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Teva Pharmaceutical and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 3, 2017, Teva disclosed the recording of a goodwill impairment charge of $6.1 billion for Q2 2017 related to the acquisition of Actavis Generics as a result of poor performance in its U.S. generics sector, as well as lower overall expected poor performance due to increased competition and delays in product launches.
On this news, the price of Teva Pharmaceutical’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
